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Abstract
Corticotropin-releasing hormone (CRH) administered into the cerebral ventricles of rats during the
first postnatal week caused a specific and stereotyped behavior sequence: rhythmic chewing and
licking (jaw myoclonus) were followed by ‘litnbic’-type seizures. The onset of the seizures was
much more rapid (2–45 min vs 3–7 h) than in adult rats, and the convulsant doses were much
lower (50 × 10−12 mol per gram brain weight vs 750 × 10−12 mol per gram brain weight in adults).
CRH potency in inducing seizures varied inversely with age. CRH-induced seizures occurred prior
to any changes in serum corticosterone, and were eliminated by the administration of a CRH
antagonist, as well as of phenytoin. Electrocorticographic correlates of CRH-induced behaviors in
the infant rat were inconsistent, suggesting a subcortical origin of CRH-induced paroxysmal
events in the immature brain.
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INTRODUCTION
Corticotropin-releasing hormone (CRH) is a hypothalamic hormone which acts on the
pituitary gland to stimulate ACTH secretion in response to stressful stimuli34–35. Once its
structure was elucidated, it became clear that, like other hypothalamic hormones, it is
distributed widely throughout the brain33. CRH receptors have been identified in the brain10,
and their number has been reported to be maximal on the fifth postnatal day10,19. A
neurotransmitter or neuromodulatory role for extrahypothalamic CRH has been
suggested8,20,21,34.
CRH has been shown to excite neurons both in vivo and in vitro29,36. The peptide increases
both spontaneous and evoked spike-discharge from locus-ceruleus neurons in vivo and
produces neuronal depolarization in CA1 and CA3 hippocampal pyramidal cells in the slice
preparation in vitro. CRH administered into the cerebral ventricles (i.c.v.) to adult rats
causes epileptiform discharges in the amygdala after a 1- to 3-h delay, which then spread to
the dorsal hippocampus12. These discharges progress, over 3–7 h to behavioral and
electrographic seizures. The doses needed for frank seizure generation in adult rats are 1.5–
3.75 × 10−9 mol (0.75–1.88 × 10−9 mol/gram brain weight)11,12.
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This study was designed to test the hypothesis that the neonatal rat is more sensitive to the
convulsant effects of CRH than the mature animal. We set out to delineate the behavioral
and electrocorticographic effects of the peptide, their specificity and their response to
anticonvulsant compounds. We utilized infant rats, starting on the 5th postnatal day.
MATERIALS AND METHODS
Animals
Timed-pregnancy rats were obtained from Zivic-Miller, (Zelionple, PA), and were housed
under a 12-h light/dark cycle, and fed ad libitum. They were handled daily to prevent
cannibalism23. Delivery times were monitored and were accurate to within 12 h. The day of
birth was considered day zero. The pups were kept with the mothers, and litters were culled
to 12 pups. Pups were mixed, such that study groups contained pups from several litters.
Pups were subjected to surgery 24 h prior to recording, and returned to their mothers. All
recordings were done at 08.30–11.30 h, to minimize diurnal variations in seizure
susceptibility27 and in endogenous glucocorticosteroid levels. CRH was injected via a
stereotaxically placed cannula in all pups, except in those utilized for hormonal
measurements alone (when the peptide was injected ‘free-hand’ as described below).
Separate groups of animals were used for dose–effect and time-to-on set experiments.
Surgery and recording
Cortical stainless steel electrodes were implanted under halothane anesthesia, using an
infant-rat stereotaxic apparatus, as previously described6,31. Two frontal and two
posteroparietal electrodes were used. The technique allows for electrocorticogram (ECoG)
recording from freely moving animals, via long, flexible wires. Recordings were carried out
in heated, shielded Plexiglas chambers, using a Grass 78E Polygraph. Pups were
continuously observed throughout the recording.
A stainless steel cannula was chronically implanted into the lateral ventricle. The stereotaxic
coordinates, using Bregma as a landmark were: (P 0.6, L 1.8, V 3.0) in 5-day-old infant rats;
(P 0.6, L 2, V 3.3) in 10-day-old pups, and (P 0.7. L 2.2, V 3.5) in 16-day-old animals.
After a 30-min habituation period, CRH or saline were administered i.c.v. in 1–2 µl, using a
micro-infusion pump. Doses used were 7.5–600 × 10−l2 mol, or 22.5–1800−12 mol/gram
brain weight. Phenytoin, 20 mg/kg (1 µl/g), was injected into the peritoneal cavity 45 min
prior to CRH, a time determined optimal for its anticonvulsant effect37,38. Phenytoin alone
at the same dose was administered to control animals, and others (2 per age) were not
injected. Alpha-helical(9–41) CRH (Peninsula, CA), a competitive CRH antagonist28, was
administered i.c.v. in 2 µl buffered saline (pH = 7.2), 30 min prior to CRH injection. Doses
used were 5 and 10 µg. Epileptic phenomena were defined as those events not seen prior to
CRH administration, recognized as epileptic in infant2,9,26 and adult rats7,18,24, and
abolished by a non-sedating (behaviorally, compared to uninjected controls) dose of
phenytoin.
Hormonal effects of CRH and CRH-induced seizures
Five-day-old pups were divided into 6 experimental groups: 3 groups received CRH (150 ×
10−12 mol) in a dye solution injected i.c.v. using a ‘freehand’ technique. Briefly, a Hamilton
25-µl syringe was fitted with a needle-cover allowing 3 mm of tip protrusion. The needle
was inserted using firm pressure 1 mm posterior and lateral to bregma — which is easily
visible on the soft and penetratable skull at this age. In our hands, as verified by the presence
of dye in the third ventricle and cisterns, this ‘freehand’ method achieved 60–70% i.c.v.
injection and is applicable for injection of large numbers of neonatal rats. Three other groups
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were injected with dye solution alone. Rats were sacrificed 15, 30 and 45 min after CRH
administration, and trunk blood collected. Plasma was frozen at −80 °C and processed for
corticosterone radioimmunoassay4. For each pup, i.c.v. injection was ascertained, and
presence or absence of CRH-induced seizures was noted. Only pups manifesting epileptic
phenomena at 15 or 30 min were included in the experimental groups.
RESULTS
Behavioral and electrographic effects of CRH
In the 5-day-old rat, CRH induced a dose-dependent spectrum of stereotyped behaviors. At
the lowest effective dose, 7.5 × 10−12 mol, pups displayed jaw myoclonus (‘chewing’). A
larger dose (22.5 × 10−12 mol) resulted in jaw myoclonus (Fig. 1), followed by tonic
extension of one or two extremities, leg clonus and focal tonic extension. Administration of
the largest dose tested — 300 × 10−12 mol — resulted in ‘chewing’ and ‘licking’ in less than
2 min, which progressed rapidly to focal tonic extension and ⁈swimming’ seizures that
lasted for over 6 h.
On the 10th postnatal day, CRH resulted in jaw myoclonus followed by ‘wet-dog shakes’,
running and ‘swimming’ seizures. By the 16th postnatal day, while jaw-myoclonus was
observed, even the maximal dose tested (300 × 10−12 mol) did not elicit motor seizures. Fig.
2 shows the dose-dependent spectrum of CRH-induced behaviors in 5-day-old pups, as
compared those observed in 10- and 16-day-old animals. As evident from the figure, larger
peptide doses were needed to elicit motor seizures in older rats: a dose causing status
epilepticus in a 5-day-old pup resulted only in jaw myoclonus in the 16-day-old pup. Table I
shows the time to onset of jaw myoclonus as a function of CRH dose and of animal age. By
the 18th postnatal day, the 4 animals tested displayed no jaw myoclonus or other epileptic
phenomena during an observation period of 9 h.
Electrocorticographic (ECoG) correlates of CRH-induced behaviors were inconsistent. Most
commonly observed were semi-rhythmic sharp waves and increased beta frequency. Fig. 3
compares the ECoG (as well as cardiac (EKG) and muscle movement (EMG) monitors)
before and after i.c.v. CRH in the 5-day-old rat pup. All ECoG changes were abolished by
pre-administration of a CRH antagonist (Fig. 3C, and see below).
Effect of anticonvulsants and CRH antagonist on CRH-induced behaviors
In the 5-day-old pup, administration of 5 µg of alpha-helical(9–41) CRH 40 min prior to the
administration of a convulsant dose of CRH, eliminated all tonic events, and attenuated
dramatically the jaw myoclonus (Table II). A larger dose (10 µg) effectively blocked also
the onset of ‘chewing’ induced by 22.5 × 10−12 mol CRH. The antagonist alone had no
behavioral or ECoG effects. Phenytoin (20 mg/kg) administered i.p. to 5-day-old infant rats
resulted in no overt behavioral changes. This dose of anticonvulsant, however, eliminated
entirely all the effects of a maximal (300 × 10−12 mol) CRH dose given i.c.v. 40 min later
(Table II).
CRH-induced behaviors are not a result of stress response
The effects of i.c.v. CRH in convulsant doses on plasma corticosterone was assessed in 5-
day-old infant rats. By 15 min after administration, 5/6 animals with verified i.c.v. cannula
placement displayed jaw myoclonus; by 30 min, all (4) animals with i.c.v. placement
manifested jaw myoclonus associated, in two, with tonic extension. As is evident from Fig.
4, corticosterone levels did not change during the first 15 min following i.c.v. CRH
administration, at a time when the pups were displaying jaw myoclonus, forepaw clonus and
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some tonic flexion. Corticosterone levels were significantly higher at the 30-min time point,
possibly related to the stress induced by the convulsive phenomena themselves.
DISCUSSION
CRH is an hypothalamic hormone which has convulsant properties in adult rats11,12,25, and
generally activates neurons, both in mammals and in lower species3,29,36. The role of
endogenous CRH in seizure generation or propagation is unknown. There is some evidence
suggesting a possible role for endogenous CRH in seizure susceptibility or generation in the
immature brain: an age-specific human seizure disorder, massive infantile spasms (MIS), is
refractory to common anticonvulsants, but responds to ACTH or glucocorticoids1,17,30.
ACTH increases plasma glucocorticoids, which have been shown to decrease CRH gene
expression, synthesis and release from the hypothalamus in both humans and rodents22,32,39.
Thus, the possibility exists that excessive CRH synthesis or activity may be a causal factor
in this type of epilepsy. MIS has been considered to be subcortical in origin1,30, but does not
respond to phenytoin1,17.
CRH presumably activates neurons through specific receptors, which are non-randomly
distributed throughout the brain10. Insel et al. have demonstrated, in the rat brain, a maximal
number of CRH receptors on the fifth postnatal day19. Moreover, studies of the ontogeny of
CRH gene expression suggest that, subsequent to a perinatal hiatus, the peptide’s synthesis
increases dramatically, starting at the end of the first postnatal week5,14. Thus, at the end of
the first postnatal week in the rat, both CRH synthesis and receptor number are maximal,
possibly contributing to enhanced convulsive potential of the peptide.
CRH-induced behaviors in the neonatal rat are specific— they are completely abolished by a
67-fold excess of a competitive antagonist. CRH-induced phenomena are probably epileptic,
since they are abolished by phenytoin, an anticonvulsant, in a dose that does not cause
sedation or elimination of normal behaviors. Moreover, the sequence of CRH-induced
behaviors is rather similar to that described following kainic acid administration in rats of
these same ages2,9, during kindling13, and over a longer time course, in CRH-treated adult
rats11,12.
The lack of consistent electrocortical correlates of the dramatic behaviors induced by CRH
during the first postnatal weeks is similar to results reported for kainic acid9, even during
status epilepticus16. In both cases, a limbic origin of the seizures is likely. The jaw
myoclonus — ‘chewing’ and ‘licking’ — are consistent with limbic, specifically amygdala
involvement13,18, and have been reported with kainic acid administration on the first
postnatal week16. The amygdala has been shown to be the first to develop spikes after CRH
administration to the adult rat11,12, although the hippocampus has been implicated by other
investigators25. The time course (less than 2 min vs 1–3 h), however, suggests that the
underlying activation mechanisms are fundamentally different in the neonatal and adult rat.
In the adult rat, CRH-induced amygdala spikes have been likened to kindling11. This
mechanism cannot be in effect in infant rats, both because of the rapid onset of CRH-
induced seizures, and because of the difficulty in achieving kindling in such immature
animals15,26.
In conclusion, our data suggest that CRH is a potent convulsant in the infant rat, and that
perturbation of CRH synthesis or activity may have some importance in seizure generation
in the immature brain.
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Fig. 1.
Photograph of a 5-day-old male rat pup displaying jaw and tongue myoclonus, following
CRH (150 × 10−12 mol) administration into the cerebral ventricles.
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Fig. 2.
Age dependence of seizure-inducing doses of CRH. Details of motor phenomena are given
in the text. Numbers in brackets denote number of animals per group.
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Fig. 3.
Electrocorticograms of 5-day-old rat pups, before (A) and 20 minutes after (B)
intracerebroventricular (i.c.v.) administration of 22.5 × 10−12 mol CRH. C: 20 min after
CRH administration, in a rat given alpha-helical CRH (10 mcg, i.c.v.) 40 min prior to the
peptide. ECoG, electrocorticogram; EKG, electrocardiogram; EMG, recording from an
electrode placed over angle of jaw, anterior to the ear. Horizontal bars = 1 s. Vertical bars =
50 µV.
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Fig. 4.
Plasma corticosterone in infant rats subjected to CRH (0.15 nmol, filled circles) or saline
(open circles) injection into the cerebral ventricles (i.c.v.). At the 30 min time-point, CRH-
injected rats have begun having motor phenomena, which were well established by 45 min.
Bars denote standard errors; *P < 0.05.
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TABLE II
Effects of phenytoin and of alpha-helical CRH on CRH-induced seizures in 5-day-old rats
n, number of animals; pmol = 10−12 mol.
Drug/
dose
n CRH/
pmol
Jaw
myoclonus
Motor
seizures
− 8   22.5 + + + + + +
Antagonist 5 µg 2   22.5 + −
Antagonist 10 µg 3   22.5 − −
Phenytoin 20 mg/kg 2 − − −
− 2 300 + + + + + +
Phenytoin 20 mg/kg 4 300 − −
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